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Abstract
Psychiatric disorders are highly heritable and associated with a wide variety of social adver-
sity and physical health problems. Using genetic liability (rather than phenotypic measures
of disease) as a proxy for psychiatric disease risk can be a useful alternative for research
questions that would traditionally require large cohort studies with long-term follow up. Here
we conducted a hypothesis-free phenome-wide association study in about 330,000 partici-
pants from the UK Biobank to examine associations of polygenic risk scores (PRS) for five
psychiatric disorders (major depression (MDD), bipolar disorder (BP), schizophrenia (SCZ),
attention-deficit/ hyperactivity disorder (ADHD) and autism spectrum disorder (ASD)) with
23,004 outcomes in UK Biobank, using the open-source PHESANT software package.
There was evidence after multiple testing (p<2.55x10-06) for associations of PRSs with 294
outcomes, most of them attributed to associations of PRSMDD (n = 167) and PRSSCZ (n =
157) with mental health factors. Among others, we found strong evidence of association of
higher PRSADHD with 1.1 months younger age at first sexual intercourse [95% confidence
interval [CI]: -1.25,-0.92] and a history of physical maltreatment; PRSASD with 0.01% lower
erythrocyte distribution width [95%CI: -0.013,-0.007]; PRSSCZ with 0.95 lower odds of play-
ing computer games [95%CI:0.95,0.96]; PRSMDD with a 0.12 points higher neuroticism
score [95%CI:0.111,0.135] and PRSBP with 1.03 higher odds of having a university degree
[95%CI:1.02,1.03]. We were able to show that genetic liabilities for five major psychiatric dis-
orders associate with long-term aspects of adult life, including socio-demographic factors,
mental and physical health. This is evident even in individuals from the general population
who do not necessarily present with a psychiatric disorder diagnosis.
Author summary
Psychiatric disorders are associated with a wide range of adverse health, social and eco-
nomic problems. Our study investigated the association of genetic risk for five common
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psychiatric disorders with socio- demographics, lifestyle and health of about 330,000 par-
ticipants in the UK Biobank using a systematic, hypothesis-free approach. We found that
genetic risk for attention deficit/hyperactivity disorder (ADHD) and bipolar disorder
were most strongly associated with lifestyle factors, such as time of first sexual intercourse
and educational attainment. Genetic risks for autism spectrum disorder and schizophre-
nia were associated with altered blood cell counts and decreased risk of playing computer
games, respectively. Increased genetic risk for depression was associated with other mental
health outcomes such as neuroticism and irritability. In general, our results suggest that
genetic risk for psychiatric disorders associates with a range of health and lifestyle traits
that were measured in adulthood, in individuals from the general population who do not
necessarily present with a psychiatric disorder diagnosis. However, it is important to note
that these associations are not necessary causal but can also represent genetic correlation
or be influenced by other factors, such as socio-economic factors and selection into the
cohort. The findings should inform future research using causally informative designs.
Introduction
Family and twin research as well as large-scale genome-wide association studies (GWAS) have
shown that psychiatric disorders are highly heritable [1] and that genetic risks for psychiatric
disorders are associated with socio-economic factors, physical health outcomes as well as other
psychiatric disorders [2–5]. Using genetic liability (rather than phenotypic measures of dis-
ease) as a proxy for psychiatric disease risk can be a useful alternative for research questions
that would traditionally require long-term follow up and big datasets due to the low prevalence
of some of the psychiatric disorders of interest in the population (e.g. adult-onset health conse-
quences of child neurodevelopmental disorders). In addition, while high genetic risk for a psy-
chiatric disorder is not always indicative of a diagnosis of psychiatric disease, it can index
underlying subthreshold symptomatology that can still impact later adversities and quality of
life [6]. Furthermore, psychiatric diagnosis may not always be available in any cohort, e.g.
there are only very few self-reported diagnosis of Attention deficit/hyperactivity disorder
(ADHD), autism spectrum disorder (ASD) or schizophrenia (SCZ) available in the UK Bio-
bank sample, which would make direct comparisons between participants with and without a
diagnosis impossible.
So far, studies have used hypothesis-driven approaches to investigate associations of genetic
risk for psychiatric disorders with various psychiatric and health outcomes as well as lifestyle
factors [7,8]. However, big data resources that are readily available, such as UK Biobank with
about 500,000 participants, provide rich phenotypic information that can be used for hypothe-
sis-free studies and offset the multiple testing burden. Phenome-wide association studies (phe-
WAS) are a type of hypothesis-free analysis where the association of a trait of interest is
systematically tested with a potentially large number of phenotypes and can be hypothesis-gen-
erating by identifying an association when there is no prior reason to expect that an association
may exist. As all available phenotypes are tested and the less ‘significant’ results published
alongside those of greater ‘significance’, pheWAS can help to reduce biases associated with
hypothesis-driven studies where researchers might only publish the most desirable or expected
results.
In a Polygenic Risk Score (PRS) pheWAS (PRS-pheWAS) genetic risk is used as a proxy for
lifelong liability for a disorder to explore associations of this genetic liability with a broad
range of traits. Understanding these associations will be essential to inform prevention or early
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intervention strategies. However, conclusions about causality are limited due to the low pre-
dictive power and high pleiotropic effects of genetic risk scores for psychiatric conditions [8].
The aim of this study was to investigate the associations between genetic risk for five com-
mon psychiatric disorders–attention-deficit/ hyperactivity disorder (ADHD), autism spectrum
disorder (ASD), schizophrenia (SCZ), major depression (MDD) and bipolar disorder (BP)—
with a wide range of socio-demographic, lifestyle, physical and mental health outcomes in UK
Biobank, using the systematic hypothesis-free PRS-pheWAS approach.
Results
In total 334,976 participants of white British ancestry in UK Biobank were included in this
study with an average age of 56 (standard deviation [SD] = 8) years. A descriptive overview of
selected UK Biobank study sample characteristics is given in Fig 1A. The UK Biobank partici-
pants are known to be more educated and healthier than the average UK population which is
reflected in the high percentage of people with a university degree (47%) and low prevalence of
current smoking (10%) in the sample, which is comparable to the full UK Biobank release [9].
Furthermore, 34% of participants reported to have seen a general practitioner and 11% a psy-
chiatrist for nerves, anxiety, tension or depression but there are few self-reported cases of
schizophrenia (n = 132), ADHD (n = 71), ASD (n = 143) or bipolar disorder (n = 439). An
overview of UK Biobank phenotype categories is given in Fig 1B.
The low number of self-reported ADHD, ASD, schizophrenia and bipolar disorder cases
did not allow a direct test of predictive power for the respective PRS and we relied on the pre-
dictive accuracy reported in other studies [10–14]. The broad question whether participants
have “Seen a psychiatrist for nerves, anxiety, tension or depression” was predicted by the
PRSMDD (OR: 1.09 [95% confidence interval [CI]: 1.08,1.10] p = 5x10
-52) and PRSSCZ (OR:
1.05 [95% CI:1.04,1.06] p = 2x10-17).
Disorder specific effects
The PRS-pheWAS of each psychiatric disorder tested the association of the respective poly-
genic risk score, aggregated from independent, genome-wide significant SNPs, with 23,004
outcomes in UK Biobank, adjusted for age, sex and the first 10 genetic principal components.
There was strong evidence after multiple testing correction based on the number of indepen-
dent tests derived from spectral decomposition (p<2.55x10-6) for associations of either the
ADHD, ASD, SCZ, MDD or BP PRS with 294 outcomes in 37 UK Biobank categories (Fig 2
and S1 Table) as described below. Of those, 290 outcomes also pass the more stringent Bonfer-
roni threshold (2.17x10-6). Correlations among the PRS can be found in supplementary S2
Table. A detailed list of all PRS-pheWAS results generated by the open-source PHESANT soft-
ware package can be found in S3 Table. Unless stated as a PHESANT result, estimates for con-
tinuous outcomes were generated by follow-up linear regressions to compute estimates on
their original scale, as PHESANT automatically applied an inverse normal rank conversion to
all continuous outcomes.
Attention deficit/ hyperactivity disorder. PRSADHD was strongly associated with 74 out-
comes (Fig 3) including 36 socio-demographic factors, 32 general health and 6 mental health,
brain and cognition outcomes. The strongest evidence of association with PRSADHD was seen
for socio-demographic and lifestyle factors. 1 SD higher PRSADHD was associated with a 1.09
month younger age at first sexual intercourse [95% CI: -1.25,-0.92] (p = 2.0x10-16), and 0.96
lower odds of having a university degree [95% CI: 0.95, 0.97] (p = 1.7x10-29). In addition,
higher PRSADHD was associated with younger age of their parents (-0.08 years [95%CI: -0.102,-
0.050] p = 5.1x10-9; -0.10 years [95% CI: -0.136,-0.069] p = 1.9x10-9, for mother and father
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respectively), 0.97 lower odds of average household income [95%CI: 0.96,0.98] (p = 5.7x10-20),
1.05 higher odds of current smoking [95%CI: 1.03,1.06] (p = 5.7x10-15) and 1.04 higher odds
of experiencing physical abuse as a child [95%CI: 1.02,1.06] (p = 4.4x10-6).
Further, 1 SD increase in PRSADHD was associated with 15 physical health outcomes related
to obesity, including 0.05 kg/m2 higher BMI [95%CI: 0.036,0.089] (p = 1.7x10-10), leg and arm
fat mass, waist circumference and trunk fat mass. Furthermore, there was evidence for an asso-
ciation of PRSADHD with blood measures, such as 0.02 cells/L higher leukocyte count [95%CI:
0.011,0.025] (p = 2.5x10-7).
Associations seen for brain and cognition include 0.04 points lower fluid intelligence score
[95%CI: -0.051,-0.026] (p = 1.9x10-9).
Autism spectrum disorder. PRSASD was strongly associated with 10 outcomes (Fig 3),
including 1 socio-demographic, 8 general health and 1 mental health outcome.
The strongest association of PRSASD was found for lower erythrocyte distribution width
where 1 SD higher PRSASD associated with 0.01% lower erythrocyte distribution width [95%
CI: -0.013, -0.007] (p = 6.3x10-10) and 0.98 lower odds of comparative body size at age 10 [95%
CI:0.97,0.98] (p = 6.6x10-11). Furthermore, 1 SD higher PRSASD was associated with 0.001 g/
cm2 lower heel bone mineral density (BMD) [95%CI:-0.002,-0.001] (p = 4.0x10-5).
The only mental health outcome that was associated with PRSASD was 1.02 higher odds of
being a nervous person (“suffer from nerves”) [95%CI:1.01,1.03] (p = 7.9x10-7).
Schizophrenia. There was strong evidence of association for PRSSCZ with 157 outcomes
(Fig 3), including 33 socio-demographic, 72 mental health and cognition and 52 general health
outcomes.
The strongest evidence of an association with higher PRSSCZ was detected for time of com-
pleting an online cognitive function test (pairs matching) (231msec [95%CI: 190,273]
p = 2.2x10-16), 1.06 higher odds of experiencing tense feelings[95%CI:1.05,1.07] (p = 3.2x10-37)
and 0.95 lower odds of playing computer games [95%CI:0.95,0.96] (p = 7.6x10-30).
In addition, a 1 SD increased PRSSCZ was associated with 1.05 higher odds of consulting a
psychiatrist for nerves, anxiety, tension or depression [95%CI:1.04,1.06] (p = 1.6x10-17).
Major depressive disorder. PRSMDD was associated with 167 outcomes (Fig 3), including
21 socio-demographic, 84 mental health and 62 general health outcomes.
Fig 1. Study overview. (A) Descriptive overview of selected outcomes in UK Biobank. (B) Categories of UK Biobank with the size of pie chart sections indicating the
number of included outcomes: socio-demographics (n = 2,057), general health (n = 19,740), mental health (n = 233), brain and cognition (n = 974).
https://doi.org/10.1371/journal.pgen.1008185.g001
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Most of the associations (74%) were related to mental health, including an association of
higher PRSMDD with higher odds of depression, anxiety, irritability, nervousness and mood
swings. Strongest evidence of association with PRSMDD was found for 1.08 higher odds of
“seen a doctor for nerves, anxiety, tension or depression” [95%CI:1.08,1.09] (p = 2.7x10-106),
0.12 points higher neuroticism score [95%CI:0.11,0.14] (p = 2.0x10-16) and 1.06 higher odds of
having mood swings [95%CI:1.05,1.07] (p = 9.8x10-58).
Fig 2. Overview of the distribution of disorder specific polygenic risk score (p<5x10-8) associated outcomes per category of the UK Biobank variables catalogue.
Shown are the number of associations with polygenic risk scores for attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), schizophrenia
(SCZ), major depression (MDD) and bipolar disorder (BP).
https://doi.org/10.1371/journal.pgen.1008185.g002
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Furthermore, there was strong evidence of 1 SD higher PRSMDD being associated with
socio-demographic and lifestyle traits including 1.03 higher odds of ever smoking [95%
CI:1.02,1.03] (p = 1.5x10-13) and 1.05 higher odds of cannabis use [95%CI:1.03,1.06]
(p = 4.1x10-10).
Associated physical health measures included 1.03 higher odds of taking medication for
pain relief, constipation or heartburn, e.g. paracetamol [95%CI:1.03,1.04] (p = 4.4x10-11) and
1.02 odds of more frequent feelings of pain, e.g. back pain [95%CI:1.02,1.03] (p = 1.1x10-9).
Bipolar disorder. PRSBP was associated with 20 outcomes (Fig 3), including 3 socio-
demographic, 14 general health and 3 mental health outcomes.
Socio-demographic and lifestyle factors included associations of higher PRSBP with 1.03
higher odds of having a university degree [95%CI:1.02,1.03] (p = 2.4x10-12), 0.02 hours/day
less time spent watching television [95%CI:-0.021,-0.010] (p = 2.8x10-8) and 0.97 lower odds of
playing computer games [95%CI:0.97,0.98] (p = 1.1x10-9).
General health traits included 11 traits indicating an association of 1 SD higher PRSBP
with 0.06kg/m2 lower BMI [95%CI:-0.07,-0.04] (p = 1.6x10-11) and 2 traits related to blood
measures, such as 0.005% decreased platelet distribution width [95%CI:-0.006,-0.003]
(p = 3.1x10-7).
Two traits related to mental health were nervous (OR:1.02 [95%CI:1.01,1.03] p = 2.3x10-7)
and tense feelings (OR:1.02 [95%CI:1.01,1.03] p = 8.0x10-7).
Cross disorder considerations
The highest overlap of associated outcomes of the univariable PRS-pheWAS scans was seen
between schizophrenia and depression (22 general health, 44 mental health and 9 sociodemo-
graphic outcomes in common), bipolar disorder (12 general health, 3 mental health and 2
sociodemographic outcomes in common) and ADHD (18 general health, 1 mental health, 2
brain and cognition and 4 sociodemographic outcomes in common). Large overlap was also
seen between ADHD and MDD (22 general health, 3 mental health and 4 socio-economic out-
comes) and BP (2 socio-economic and lifestyle and 7 general health outcomes) (Fig 4). How-
ever, the majority of the associations are directionally opposite for ADHD and BP. For
example, higher PRSADHD showed evidence for associations with lower educational attainment
and higher BMI, whereas higher PRSBP was associated with higher educational attainment and
lower BMI.
Furthermore, all disorder PRSs showed some evidence for association with different blood
cell counts, such as a decreased leukocyte count for PRSADHD and PRSMDD, or a decreased
eosinophil count for PRSADHD and PRSSCZ.
There was very little overlap of highly associated outcomes between the neurodevelopmen-
tal domains (ADHD and ASD).
Sensitivity analysis
We repeated our tests of association for outcomes passing the spectral decomposition thresh-
old, additionally adjusting for potential confounders (assessment centre, genotype chip and
Fig 3. PRS-PheWAS results for attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD),
schizophrenia (SCZ), major depressive disorder (MDD) and bipolar disorder (BP). Left hand panel: QQ plots of expected versus
observed p-values for association of PRS with all outcomes in UK Biobank. Red line indicates the significance threshold derived by
spectral decomposition (2.5x10-6). Right hand panel: selected results from different categories with p-values below the significance
threshold and estimates generated by PHESANT. Results for continuous outcomes (std. β) are the standard deviation change of
inverse-rank normal transformed outcome per 1 SD higher PRS.
https://doi.org/10.1371/journal.pgen.1008185.g003
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the first 40 principal components). These have not been included in the original analysis to
reduce the possibility of them introducing collider bias. Estimates were highly consistent with
our main results, as shown in S4 and S5 Tables.
Relaxing the p-value threshold for including SNPs in the PRS resulted in some changes in
the results (S1 Fig). For ADHD, SCZ, MDD and BP the general trend was an inflation of p-val-
ues (S6 Table) and higher effect estimates with smaller confidence intervals. A different pattern
was observed for autism spectrum disorder with inconsistent results for some of the outcomes,
Fig 4. Cross-disorder comparison. Shown are standardized log odds (upper section in each panel) or standardized beta-values (lower section of each panel) of all
outcomes associated with polygenic risk scores for either attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), schizophrenia (SCZ),
major depressive disorder (MDD) or bipolar disorder (BP) at p<2.55x10-6 as indicated by stars (�). For outcomes categorized as multi-category, only one category is
displayed. Only associations with anthropometric measures of the right side of the body are shown. Estimates were generated by PHESANT. Results for continuous
outcomes (std. beta) are the standard deviation change of inverse-rank normal transformed outcome per 1 SD higher PRS.
https://doi.org/10.1371/journal.pgen.1008185.g004
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as described in detail in the supplementary S1 Text. Overall the strength of associations
obtained for blood cell count traits across disorders varied between p-value thresholds, with
weaker associations found for less stringent p-value thresholds.
When applying the more stringent Bonferroni correction for multiple testing we found that
the number of strongly associated outcomes with the PRS reduced slightly to 71 outcomes for
PRSADHD, 9 for PRSASD, 155 for PRSSCZ, 166 for PRSMDD and 19 for PRSBP. Outcomes that
did not pass Bonferroni but phenoSPD were “Weight”, “Trunk fat mass” and “Forced expira-
tory volume in 1 second” for ADHD; “Forced vital capacity (FVC)” for ASD; “Word interpola-
tion” and “Valsartan prescription” for SCZ; “Action taken following self-harm” for MDD and
“Spherical power (left)” for BP.
In order to reduce potential biases due to sample overlap with the MDD GWAS from Wray
et al. [5], we computed a PRS based on the Wray et al. sample excluding UK Biobank and
23andMe participants (PRSMDDnoUKB). The corresponding pheWAS resulted in 51 outcomes
passing the multiple testing threshold (S7 Table). Overall, effect estimates were attenuated for
many previously identified outcomes and about one third of them did not pass the multiple
testing threshold anymore. On the other hand, new associations especially with anthropomet-
ric traits could be observed.
Discussion
In this study, we conducted a PRS-pheWAS to examine the relationships between genetic lia-
bility for five major psychiatric disorders and 23,004 outcomes in about 330,000 UK Biobank
participants.
Our results build on a large body of literature supporting links between genetic risk for psy-
chiatric disorders with a wide variety of outcomes including psychological well-being, lifestyle,
socio-demographic factors and physical health [2,4,7,15,16]. Our findings also suggest that
although psychiatric disorders show strong genetic overlap [7], genetic risk for distinct psychi-
atric disorders show differential associations with lifestyle, socio-demographic factors and
physical health as highlighted in Fig 5. Genetic liability for ADHD and bipolar disorder
showed the strongest associations with lifestyle and social environmental factors as well as
physical health. On the other hand, genetic liability for major depression and schizophrenia
was most strongly associated with psychological health and associations with lifestyle and
socio-demographic factors were less robust.
We were able to replicate previously reported associations between genetic liability for
ADHD and lower educational attainment [17,18], higher prevalence of smoking [19], younger
age at delivery [20] and higher body mass index [21]. While the previous findings for smoking
and BMI were identified in young adults, our findings using an adult population-based sample
with a mean age of 56 years, suggest that associations of childhood psychiatric disorder genetic
liabilities with health and social outcomes persist into later adulthood. Associations of genetic
liability for ADHD in childhood could represent effects of childhood ADHD or sub-threshold
ADHD on long-term social and economic outcomes, or alternatively associations could be
due to parental effects or horizontal pleiotropy (the same genetic variants affecting multiple
traits). Hence, some of the observed associations in this study might also be more likely to act
as a risk factor for the corresponding disorder, rather than being the consequence of it.
Interestingly ADHD genetic liability was also associated with a history of physical maltreatment.
This result adds to findings from previous twin and adoption designs that have suggested that
ADHD and ADHD genetic liability may have “evocative” effects on parent-child hostility [22–24].
Many of the associations of genetic liability for MDD with increased mood swings, irritabil-
ity, feelings of loneliness and isolation are clinically known and have previously been reported
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[5]. Our results are also in line with a recent publication from the Brainstorm consortium
investigating genetic correlations among psychiatric disorders with neurological and quantita-
tive traits using LD score regression and GWAS summary statistics, reporting high genetic
correlations between most psychiatric disorders and educational attainment and BMI [2,7].
However, we found little evidence for associations of genetic liability for ADHD and ASD with
mental health outcomes, such as depressive symptoms, neuroticism or anxiety; and very few
associations with cognitive or brain imaging outcomes, which might be because of the UK Bio-
bank being a selected sample with lower rates of psychiatric disorders than the general popula-
tion as discussed in the limitations section.
In addition to identifying previously reported associations, our PRS-pheWAS also revealed
novel associations. We found a strong association of genetic liability for ASD with decreased
heel bone mineral density, which furthers previous evidence from observational studies that
children and adolescents with ASD have lower bone mineral density [25,26], higher frequency
of bone fractures [27] and lower vitamin D levels [28,29], which is essential for bone metabo-
lism. This might suggest that these observed associations may be due to pleiotropic effects of
genetic variants associated with bone health.
In line with our results, other previous work in schizophrenia patients and their relatives
identified an association between schizophrenia and longer performance duration on the Trail
Making Test [30], which requires searching and connecting irregularly arranged targets (digits
Fig 5. Categories of highly associated outcomes with polygenic risk scores for attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD),
schizophrenia (SCZ), major depressive disorder (MDD) and bipolar disorder (BP). Size of categories depends on the relative number of associated outcomes to the
total number of outcomes within each category. Only categories with more than 1 variable are shown. Lifestyle and socio-demographic factors are shown in orange,
physical health measures are shown in green and mental health, brain and cognition traits are shown in violet. Grey categories had zero hits for the corresponding
disorder.
https://doi.org/10.1371/journal.pgen.1008185.g005
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and letters) in ascending order and is widely used to test for executive function, cognitive abil-
ity and processing speed [31–36].
Altered blood cell counts were associated with genetic liability for all disorders. Many psy-
chiatric disorders have been previously associated with allergic or inflammatory states [37–39],
such as asthma [40] and atopic diseases [41,42] but it is unclear whether high inflammatory
states are on the causal pathway to disorder manifestation or the result of comorbid and con-
founding behaviours associated with the disease, such as restricted diet, overweight, risky
behaviours or medication. Our results support the possibility that altered blood cell counts
could be a consequence of the disorder, but we cannot rule out contributions of horizontal
pleiotropic effects that weaken or intensify the observed association when adding more SNPs
into the PRS. Also, considering the inconsistent findings from the sensitivity analyses for
blood count traits, results need further validation and should be treated with caution.
In addition to previous observations between psychiatric disorders and later outcomes that
we were able to identify in our pheWAS, there are many reported and established associations
that we did not observe in our study. For example, we did not observe an association between
genetic risk for psychiatric disorders, apart from a negative association with PRSSCZ, and type
2 diabetes mellitus (T2D). Reasons for this lack of observations may include selection bias as
discussed in the next paragraph, confounding of observational studies or complex relation-
ships between disorders. Although there is evidence of genetic overlap between T2D and SCZ
[43] the causal pathway is potentially complex and bidirectional, and needs to be investigated
using a formal causal framework. However, being able to identify true causal relationships and
shared biological pathways between psychiatric disorders and other health or socio-economic
outcomes is essential in designing interventions. Hence, we encourage researchers to triangu-
late our findings using other causally informative studies.
Limitations
Patients with psychiatric disorders or high genetic liability for psychiatric disorders are known
to be less likely to participate in studies in the first place and more likely to drop-out during an
ongoing study [44]. Selection into a study as well as attrition can induce collider bias [45].
There is consensus that the UK Biobank sample is not representative of the UK population,
with participants showing, for example, lower prevalence of current smoking and lower rates
of mortality [9]. If both having a psychiatric disorder and a specific outcome (e.g. high socio-
economic position) are associated with participation (the collider), this can induce an associa-
tion between genetic risk for psychiatric disorders and the outcome (S2 Fig). Supplementary
S8 Table provides an overview of the expected direction of the collider bias on the effect esti-
mates for a simple model with positive or negative association with participation of the expo-
sure or outcome variable, which can be used as a guide to expected direction of bias under
some circumstances.
A direct comparison of PHESANT estimates across the psychiatric disorders cannot be
done without taking the differentially powered GWASs and derived PRS into account. This
can affect the number and set of outcomes associated with each disorder, which only allows
for a relative comparison among the PRS. We also cannot calculate the predictive power of the
ADHD, ASD, schizophrenia and bipolar PRS in the UK Biobank sample due to very low num-
ber of self-reported diagnoses of these disorders. Further, the MDD GWAS used in the current
study to calculate genetic risk scores included thirty thousand participants from UK Biobank
(about 10% of the GWAS sample) which might have inflated our results for depression related
items but is not expected to introduce bias in any other traits, such as blood counts. However,
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sensitivity analysis using a GWAS excluding the UK Biobank sample and hence much smaller
sample size did confirm many of the found observations.
Although genetic risk scores were derived using variants associated at genome-wide signifi-
cance level, they can still have horizontal pleiotropic effects on different disorders and traits.
Hence, our reported associations cannot on their own inform about causality but should be
followed up with other causally informative methods to assess the true direction of the causal
effect as well as pleiotropy and heterogeneity between genetic variants. We therefore encour-
age triangulation of results using other study designs [46,47], such as two-sample MR, negative
control or twin studies.
Conclusion
We were able to show that genetic liability for five common psychiatric disorders is associated
with distinct domains of adult life, including socio-demographic factors, mental and physical
health. This is evident even in individuals from the general population who do not necessarily
present with a psychiatric disorder diagnosis, or for individuals who may have been diagnosed
as a child but whose symptoms have decreased since. Our research has potential implications
for both risk factors and consequences of mental health problems. Our findings indicate
potential factors associated with genetic liability for psychiatric disorders, including some
which have been identified before (e.g. irritability and depression) and also novel hypotheses
(e.g. the association of genetic risk for ASD and reduced bone mineral density) that could be
tested using different study designs. Finally the findings also support well-established research
into the high long-term economic, societal and individual costs associated with mental health
problems [48] and highlight that it is important for mental health scientists and clinicians to
consider a broad range of lifestyle, socio-demographic and health risks beyond core diagnoses,
in those at elevated familial/genetic risk as well as those with a psychiatric disorder.
Methods
Ethics statement
UK Biobank received ethical approval from the research ethics committee (reference 13/NW/
0382). All participants provided informed consent to participate. This work was done under
application number 16729 (using genetic data version 3 and phenotype dataset 21753).
Study population
Between 2006–2010 UK Biobank recruited 503,325 men and women in the England, Wales
and Scotland at ages 40–69 years. The cohort contains a large dataset including physical mea-
surements, blood/urine/saliva samples, health and lifestyle questionnaires as well as genotype
(https://www.ukbiobank.ac.uk/).
For 463,010 participants genotyping was performed using the Affymetrix UK BiLEVE
Axiom array or Affymetrix UK Biobank Axiom array. Participants with non-white British
ancestry, defined as a self-reported non-white British ancestry in combination with a genetic
principal component analysis (PCA) analysis conducted by UK Biobank (n = 54,757 non-
white British or non-Caucasian) [49], and participants who had a kinship coefficient denoting
a third-degree relatedness (based on Manichaikul et al. [50]; kinship coefficient < 0.0625,
n = 73,277) were removed from an already quality checked dataset (excluding participants
with withdrawn consent, sex mismatch or sex aneuploidy) [49,50], resulting in a dataset con-
taining 334,976 participants (Fig 6).
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Polygenic risk scores
Genetic variants were identified from the most recent GWAS summary statistics listed in
Table 1 with p<5x10-8 for ADHD, ASD, SCZ, MDD and BP. This stringent p-value cut-off
was chosen to minimize bias introduced by horizontal pleiotropic effects of genetic variants.
All summary statistics were subject to standard quality control including filtering for minor
allele frequency (MAF>0.1) and imputation quality (INFO>0.8) and excluding the MHC
region on chromosome 6 (26-33Mb) due to its complex linkage disequilibrium structure.
Fig 6. Overview of study sample derivation. Participants with withdrawn consent, sex mismatch or sex aneuploidy
were already removed from the dataset in standard QC steps. [49].
https://doi.org/10.1371/journal.pgen.1008185.g006
Table 1. Details of GWAS used for calculating PRS.
disorder cases controls SNPs in PRS1 Heritability Source
ADHD 20,183 35,191 10 5.5%2 Demontis et al. (2019) [2]
ASD 18,381 27,969 2 2.5%2 Grove et al. (2017) [4]
Schizophrenia 36,989 113,075 99 7%3 Ripke et al. (2014) [3]
MDD 135,458 344,901 44 1.9%3 Wray et al. (2018) [5]
Bipolar disorder 20,129 21,524 8 4%3 Ruderfer et al. (2018) [53]
1- PRS derived from genome-wide significant hits (p<5x10-8)
2- SNP heritability estimates (Nagelkerke’s R2) reported in the corresponding discovery sample
3-Percent of variance on the liability scale explained by PRS reported in corresponding discovery sample
ADHD–Attention deficit/hyperactivity disorder, MDD–Major depression, ASD–Autism spectrum disorder
https://doi.org/10.1371/journal.pgen.1008185.t001
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Polygenic risk scores (PRS) were derived using independent risk alleles at p<5x10-8 in approx-
imate linkage disequilibrium (R2<0.1 within 500kb distance) and computing a weighted, stan-
dardized mean score from these, as has been described previously [51,52].
Outcomes
UK Biobank provides a fully searchable data showcase (http://biobank.ctsu.ox.ac.uk/crystal/)
which at the time of data download (March 2018) included 23,004 outcomes (see supplemen-
tary S2 Text), including lifestyle and environment, socio-demographic, early life factors,
anthropometry, family history and depression outcomes.
Age, sex and the first 10 principal components derived from the genetic data were included
as covariates in all regression models. Age was derived from the participants date of birth and
the date of their first assessment centre visit. Sex was self-reported and validated using genetic
data.
PHESANT PRS-pheWAS
PHESANT package (version 0.17) was used to test the association of each PRS with each out-
come variable in Biobank. A detailed description of PHESANT’s automated rule-based
method is given elsewhere [54,55]. In brief, decision rules are based on the variable field type
and categorize each variable as one of four data types: continuous, ordered categorical, unor-
dered categorical or binary. PHESANT then estimates the univariate association of the PRS
(independent) with each outcome variable (dependent) in a regression model, respectively.
Normality of continuous data is ensured by an inverse normal rank transformation prior to
testing. To compute meaningful and better interpretable estimates, outcomes passing the mul-
tiple testing threshold that qualified as continuous outcomes were followed up on their original
scale using a linear regression, excluding outliers and checking for normal distribution of
residuals. All estimates correspond to 1 SD change of the PRS.
PHESANT assigns each UK Biobank outcome to one of 91 level 3 categories based on the
235 origin categories of the UK Biobank catalogue (a full list of categories is provided in S1
Table). Furthermore, three authors (BL, EW, ES) grouped these 91 categories into four pre-
specified higher level categories in order to aid result presentation: socio-demographics and
lifestyle, brain and cognition, mental health and general health (Fig 1B).
To account for multiple testing (n = 23,004 tests) we used a previously derived threshold
[55,56] based on an estimate of the number of independent phenotypes calculated using spec-
tral decomposition (phenoSPD) (n = 19,645). The multiple testing adjusted significance
threshold was p<2.55x10-6 (0.05/19,645). The amount of inflation of observed versus expected
p-values is given as the ratio of the median chi-squared statistics for observed to expected
median p-values, referred to as Lambda (λ). A conservative Bonferroni correction of multiple
testing that assumes uncorrelated traits, would yield a similar p-value threshold of p<2.17x10-
6 (0.05/23,004).
PHESANT sensitivity analysis
Analyses were re-run to assess residual confounding of assessment centre and genetic batch,
including them as well as all 40 principal components as additional covariates for outcomes
identified as strongly associated with either one of the disorders PRS. These covariates were
not included in the first model because this could introduce collider bias if, for example, loca-
tion of assessment centre is affected by both genetic predisposition and outcomes, as discussed
in the limitations section.
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Furthermore, PRS were derived using various p-value thresholds (p<0.01, p <0.1x10-3,
p<1x10-4, p<1x10-5, p<1x10-6) with consequently increasing numbers of SNPs (S9 and S10
Tables) and the five PRS-pheWAS were re-run with the more relaxed PRS to capture a larger
amount of explained variation in the disorders by accepting an increase in horizontal pleiotro-
pic effects and adjunct noise. For MDD GWAS results were available for only 10,000 SNPs at
these additional thresholds due to availability restrictions.
To assess biases due to a sample overlap between the Wray et al. MDD GWAS and UK Bio-
bank, we computed a PRS based on the Wray et al. sample excluding the UK Biobank and
23andMe samples (43,204 cases and 95,680 controls, nSNPs in PRS = 3) as described in How-
ards et al. [57] and re-run the pheWAS based on this.
All analyses were performed in R version 3.2.4 ATLAS and R version 3.3.1, and the code is
available at [https://github.com/MRCIEU/Psychiatric-disorder-pheWAS-UKBB]. Git tag v0.2
corresponds to the version presented here.
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